ALK translocation has become a promising candidate for a therapeutic target as well as a diagnostic molecular marker described for NSCLC cancer patients [4] due to the excellent responses observed in lung tumors with the ALK rearrangement treated with ALK inhibitors [28]. This evidence concerns the gene ALK and non-small cell lung carcinoma.